NCT04885114View on ClinicalTrials.gov

Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 30, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Huntington Disease
Interventions
GENETIC

Intraparenchymal rAAV1 - (mi)RNA HTT

Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.

Sponsors
All Listed Sponsors
lead

Voyager Therapeutics

INDUSTRY